DOMEBORO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DOMEBORO (DOMEBORO).
DOMEBORO is a topical astringent solution containing aluminum acetate. It works by precipitating proteins and reducing local inflammation, exudation, and infection in dermatological conditions.
| Metabolism | Not systemically absorbed; no significant metabolism. |
| Excretion | Renal excretion of absorbed boron: >90% as boric acid; no significant biliary/fecal elimination. |
| Half-life | 20–45 hours (boric acid); prolonged in renal impairment. |
| Protein binding | <10% (boric acid binds weakly to plasma proteins). |
| Volume of Distribution | 0.5–0.8 L/kg (boric acid distributes throughout total body water). |
| Bioavailability | Topical: minimal (<5%) systemic absorption through intact skin; higher if applied to broken skin or mucosa. |
| Onset of Action | Topical: astringent effect within minutes; systemic effects not clinically relevant at recommended doses. |
| Duration of Action | Topical: 2–4 hours; limited by solution evaporation. |
Apply 2 tablets or 2 packets dissolved in 1 pint (473 mL) of cool water to affected area as a wet dressing or soak for 15-30 minutes 2-3 times daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for topical use; systemic absorption is minimal. |
| Liver impairment | No dose adjustment required for topical use; systemic absorption is minimal. |
| Pediatric use | Same as adult dosing: dissolve 2 tablets or 2 packets in 1 pint (473 mL) cool water, apply topically for 15-30 minutes 2-3 times daily. Use with caution in children under 2 years. |
| Geriatric use | No specific dose adjustment recommended; use same as adult dosing. Monitor skin integrity due to thinner skin. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DOMEBORO (DOMEBORO).
| Breastfeeding | Excretion in human milk unknown. Due to potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue drug, taking into account importance of drug to mother. M/P ratio not available. |
| Teratogenic Risk | No evidence of teratogenicity in animal studies; limited human data. Risk cannot be excluded; use only if clearly needed. First trimester: avoid if possible. Second/third trimester: no known fetal risks from topical use. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to aluminum acetate or any component"]
| Precautions | ["For external use only","Avoid contact with eyes","Discontinue if irritation or sensitization occurs","Do not use on large areas of broken skin","Not for prolonged use"] |
Loading safety data…
| No specific maternal or fetal monitoring required beyond standard prenatal care. Monitor for local irritation or allergic reactions if used extensively. |
| Fertility Effects | No known effects on fertility based on available data. |